Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation, Tislelizumab, and Lenvatinib for Melanoma Liver Metastasis
NCT05406466Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Jul 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, lenvatinib in melanoma, sponsored by Fudan University. Status: unknown.
02
Drugs
tislelizumablenvatinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05406466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05406466.